Prescribing, Policies and Pathways
or
Medicine / Guideline | Indication | RAG rating | Document type | Place |
---|---|---|---|---|
Acetylcholinesterase (AChE) inhibitor | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
Acetylcholinesterase (AChE) inhibitor | Alzheimer's disease dementia | Amber initiation | Prescribing support document | East and North Hertfordshire, South and West Hertfordshire |
Acute trial of rimegepant for treatment of migraine - patient questionnaire | Migraine - treating | Green | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Alemtuzumab | Highly active relapsing remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Amantadine | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Amifampridine | Lambert-Eaton myasthenic syndrome (NHSE) | Double Red | n/a | Hertfordshire and West Essex ICB |
Anticholinergic burden (ACB) | Structured medication review Eclipse Live | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Anticholinergic burden (ACB) | Structured medication review Hints and tips | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Apomorphine | Parkinson's disease | Red | Decision document | Hertfordshire and West Essex ICB |
Atogepant | Migraine - chronic | Amber initiation | Prescribing pathway | Hertfordshire and West Essex ICB |
Atogepant | Migraine - episodic | Amber initiation | Prescribing pathway | Hertfordshire and West Essex ICB |
Atogepant | Migraine-prevention | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Atomoxetine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
Atomoxetine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Attention deficit hyperactivity disorder (ADHD) | FAQs | n/a | Primary Care prescribing resource | South and West Hertfordshire |
Attention deficit hyperactivity disorder (ADHD) | ADHD shared care protocol | Amber protocol | Shared care protocol | West Essex |
Attention deficit hyperactivity disorder (ADHD) | ADHD shared care protocol - children, young people and adults | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Bobath Therapy | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Botulinum toxin type A | Focal spasticity, Hemi-facial spasm, Blepharospasm, Cervical dystonia, Frey’s syndrome, Chronic anal fissure, Dysphagia, Hirschsprung’s disease, Overactive bladder,Masseteric hypertrophy and temporomandibular disorders | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Brain MRI for the exclusion of Brain and CNS Cancer | n/a | n/a | South and West Hertfordshire | |
Cannabidiol (Epidiyolex®) | Tertiary care indication (NHSE) Suitable for shared care between tertiary and secondary care providers. Adjunctive treatment with clobazam for treating seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS) | Red | Decision document | Hertfordshire and West Essex ICB |
Cannabis-based medicinal preparations | Intractable nausea & vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy | Red | Position statement | Hertfordshire and West Essex ICB |
Carbamazepine | Epilepsy | Green | n/a | Hertfordshire and West Essex ICB |
Cenobamate | Focal onset seizures | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Cladribine | Relapsing–remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Clomipramine | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Clonazepam | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Co-beneldopa | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Co-careldopa | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Co-careldopa (Carbidopa/levodopa) intestinal gel | Parkinson's disease (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Co-careldopa Intestinal Gel (Duodopa) | Parkinson's Disease (NHSE tertiary centre only) | Red | n/a | Hertfordshire and West Essex ICB |
Co-proxamol | Pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Co-proxamol | Pain | n/a | Patient information | Hertfordshire and West Essex ICB |
Cytisine | Smoking cessation | Double Red | n/a | Hertfordshire and West Essex ICB |
Daridorexant | Long-term insomnia | Green | Prescribing support document | Hertfordshire and West Essex ICB |
Daridorexant | Insomnia | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
Daridorexant | Long-term insomnia | Green | Patient information | Hertfordshire and West Essex ICB |
Delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD] spray (Sativex®) | Spasticity in multiple sclerosis (MS) | Red | Decision document | Hertfordshire and West Essex ICB |
Dependence forming medicine | Pain - ECF FAQs | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Dexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
Dexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Dexamfetamine | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Domperidone | Nausea vomiting in children | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Donepezil | Alzheimer's disease dementia | Amber initiation | Prescribing support document | East and North Hertfordshire, South and West Hertfordshire |
Donepezil | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
Dosulepin stopping and switching guidance | Depression | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Drug Titration and Review for Neuropathic Pain | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Electronic Cigarettes and other novel nicotine containing products | Tobacco dependance | Red | Position statement | Hertfordshire and West Essex ICB |
Entacapone | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Epilepsy, Fits and Seizures | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Eptinezumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Eptinezumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Erenumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Erenumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Ethosuximide | Absence seizures, atypical absence seizures (adjunct) and myoclonic seizures in adults and children. | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Ethosuximide capsules | Absence seizures, atypical absence seizures (adjunct) and myoclonic seizures in adults and children. | Amber initiation | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Ethosuximide syrup | Absence seizures, atypical absence seizures (adjunct) and myoclonic seizures in adults and children. | Amber initiation | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Fampridine | Multiple sclerosis (NHSE) | Double Red | Decision document | Hertfordshire and West Essex ICB |
Fentanyl immediate release (IR) | Pain (except for palliative care) | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Fentanyl Immediate-Release Patient Information Leaflet | Pain (except for palliative care) | n/a | Patient information | Hertfordshire and West Essex ICB |
Fingolimod | Highly active relapsing–remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Fremanezumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Fremanezumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Gabapentin | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Galantamine | Alzheimer's disease dementia | Amber initiation | Decision document | East and North Hertfordshire, South and West Hertfordshire |
Galantamine | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
Galcanezumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Galcanezumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB, East and North Hertfordshire, South and West Hertfordshire, West Essex |
Glatiramer | Multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Glycopyrronium bromide oral | Hypersalivation - adults | Double Red | n/a | Hertfordshire and West Essex ICB |
Guanfacine | Atttention deficit hyperactivity disorder (ADHD) - in children | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Guanfacine | Atttention deficit hyperactivity disorder (ADHD) - in children | Amber protocol | Shared care protocol | West Essex |
Headache | n/a | Clinical pathways | Hertfordshire and West Essex ICB, South and West Hertfordshire | |
Lacosamide | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Lamotrigine | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Levetiracetam | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Lidocaine plaster patient information Leaflet | Pain | n/a | Patient information | Hertfordshire and West Essex ICB |
Lidocaine Plasters | All except post herpetic neuralgia and non post herpetic neuralgia localised neuropathy | Double Red | n/a | Hertfordshire and West Essex ICB |
Lidocaine plasters deprescribing guide | Neuropathic pain | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Lisdexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
Lisdexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Long term insomnia management | Long-term insomnia | n/a | Patient information | Hertfordshire and West Essex ICB |
Mechanical Insufflation-Exsufflation (MI-E) Devices / CoughAssist | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Medication Overuse Headache | n/a | Decision document | South and West Hertfordshire | |
Melatonin | Insomnia - Neurodevelopmental Disorders in patients under the age of 18 years | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Melatonin | Insomnia - Learning disability in adults and paediatrics | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Melatonin | Insomnia - product options in neurodevelopmental disorders in patients aged 2 to under 18 years | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Melatonin | Insomnia - product options in adult and paediatric patients with learning disabilities | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Melatonin | Insomnia adults excluding learning disabilities | Double Red | n/a | Hertfordshire and West Essex ICB |
Melatonin (Slenyto) | Insomnia | Double Red | Decision document | Hertfordshire and West Essex ICB |
Memantine | Alzheimer's disease dementia | Amber initiation | Prescribing support document | East and North Hertfordshire, South and West Hertfordshire |
Memantine | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
Methylphenidate | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
Methylphenidate | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Methylphenidate | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Mexiletine | Myotonia in non-dystrophic myotonic disorders (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Midazolam (Buccolam) | Epilepsy (prescribe by brand) | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Midazolam (Epistatus) | Epilepsy (prescribe by brand) | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Migraine | Migraine - chronic | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Migraine | Migraine - episodic | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Migraine treatment in adults | Migraine | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Migraine with or without Aura | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Modafinil | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Motor Neurone Disease (MND) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Multiple Sclerosis (MS) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Nabilone | Intractable chemotherapy induced nausea and vomiting | Red | Decision document | Hertfordshire and West Essex ICB |
Natalizumab | Multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Neuropathic pain | Neuropathic pain | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Neuropathic Pain Drug Titration and Review | n/a | Clinical pathways | East and North Hertfordshire | |
Nitrazepam | Insomnia | Double Red | n/a | Hertfordshire and West Essex ICB |
Omega 3 fatty acid | Primary or secondary prevention of CVD, sleep problems, multiple sclerosis (MS), familial hypercholesterolemia | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Omega-3 Fatty Acids Patient Information Leaflet | Primary or secondary prevention of CVD, sleep problems, multiple sclerosis (MS), familial hypercholesterolemia | n/a | Patient information | Hertfordshire and West Essex ICB |
Open MRI | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Open Mri Prior Approval Form | n/a | Prior approval form | Hertfordshire and West Essex ICB | |
Opicapone | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Opioid | Pain - persistent self care | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Opioid | Pain - plan agreement | n/a | Patient information | Hertfordshire and West Essex ICB |
Opioid | Pain - review letter | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Opioid Aware Campaign | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB | |
Opioid Deprescribing | Pain - long-term prescribing for non-cancer, chronic pain in adults | n/a | Position statement | Hertfordshire and West Essex ICB |
Opioid fact sheet | Pain | Green | Patient information | Hertfordshire and West Essex ICB |
Opioid reduction | Opioid reduction tool | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Orphenadrine | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Oxcarbazepine | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Oxycodone and naloxone | Pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Oxycodone and Naloxone combination products Patient Information Leaflet | Pain | n/a | Patient information | Hertfordshire and West Essex ICB |
Paracetamol and tramadol | Pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Paracetamol and Tramadol combination products Patient Information Leaflet | Pain | n/a | Patient information | Hertfordshire and West Essex ICB |
Peginterferon and ropeginterferon | Hepatitis and Multiple sclerosis (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Pentosan polysulfate sodium | Bladder pain syndrome | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Phenobarbital | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Phenytoin | Epilepsy | Green | n/a | Hertfordshire and West Essex ICB |
Pitolisant | Excessive daytime sleepiness caused by obstructive sleep apnoea | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Pramipexole | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Prednisolone | All indications - soluble tablet | n/a | Patient information | Hertfordshire and West Essex ICB |
Prednisolone enteric coated | All indications | Double Red | n/a | Hertfordshire and West Essex ICB |
Primidone | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Procyclidine | Parkinson's disease | Green | n/a | Hertfordshire and West Essex ICB |
Promethazine | All indications | n/a | Position statement | Hertfordshire and West Essex ICB |
Rapid Onset Isolated Visual Loss (No other neurological symptoms or signs) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Rasagiline | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Riluzole | Amyotrophic Lateral Sclerosis (ALS) form of Motor Neurone Disease (MND) | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
Rimegepant | Migraine - acute treatment | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
Rimegepant | Migraine- episodic - prevention | Amber initiation | Prescribing pathway | Hertfordshire and West Essex ICB |
Rimegepant | Migraine- episodic - prevention | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Rivastigmine | Alzheimer's disease dementia | Amber initiation | Prescribing support document | East and North Hertfordshire, South and West Hertfordshire |
Rivastigmine | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
Ropinirole | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Rotigotine | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Sativex® and other licensed cannabis -based medicinal products | Red | Decision document | Hertfordshire and West Essex ICB | |
Selective serotonin reuptake inhibitors (SSRIs) | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Selegiline | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Shared care | Attention deficit hyperactivity disorder (ADHD) by Private Provider | Amber protocol | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Siponimod | Multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Sodium oxybate | Narcolepsy with cataplexy (tertiary centre only) | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Sodium valproate | All indications | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Solriamfetol | Excessive daytime sleepiness caused by narcolepsy (tertiary centre only) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Solriamfetol apnoea | Excessive daytime sleepiness caused by obstructive sleep apnoea | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Spinal Cord Stimulation | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Stroke | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Tapentadol IR | Pain - acute moderate to severe | Double Red | n/a | Hertfordshire and West Essex ICB |
Teriflunomide | Relapsing–remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
TIA (Transient Ischemic Attack) | n/a | Clinical pathways | East and North Hertfordshire | |
Topiramate | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Transcranial Magnetic Stimulation (TMS and rTMS) | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Tremor in Primary Care |Initial Assessment | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Trihexyphenidyl (Benzhexol) | Parkinson's disease | Green | n/a | Hertfordshire and West Essex ICB |
Trimipramine - stopping and switching guidance | Depression | Double Red | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Venlafaxine | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Vigabatrin | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |